...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Biochemical Pharmacology >The many faces of Janus kinase
【24h】

The many faces of Janus kinase

机译：Janus激酶的许多面孔

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Janus kinases have proved to be essential for many immunological processes but there is growing evidence that they also play a critical role in pathogenesis of many diseases including inflammatory diseases and cancer where they promote multiple steps of tumorigenesis. Several companies are in late stage clinical programs for the development of JAK kinase inhibitors and the first small molecule JAK inhibitor, Jakafi ? (ruxolitinib) has been just approved for treatment of myeloproliferative neoplasms. Several other molecules are on the rise to treat arthritis, psoriasis and multiple types of cancer. This commentary will provide a review of the JAK kinase field as it pertains to small molecule inhibition for the treatment of cancer and autoimmune diseases with an emphasis on JAK2. The use of experimental and clinical inhibitors of JAK will be discussed for solid tumor and hematological malignancies, lupus, arthritis, colitis, neurological disorders, pain, diabetes and cardiovascular disease. In addition, it will review current paradigms in the field and treatment programs which could be complemented by small molecule inhibitors of Janus kinase.
机译：Janus激酶已被证明对许多免疫学过程至关重要，但越来越多的证据表明，Janus激酶在许多疾病的发病机理中也起着关键作用，其中包括炎症性疾病和癌症，它们可促进肿瘤发生的多个步骤。几家公司正在开发JAK激酶抑制剂和第一个小分子JAK抑制剂Jakafi？的后期临床计划。 （ruxolitinib）刚刚被批准用于治疗骨髓增生性肿瘤。治疗关节炎，牛皮癣和多种癌症的其他几种分子正在兴起。这篇评论将提供JAK激酶领域的综述，因为它与小分子抑制有关，特别是针对JAK2的癌症和自身免疫性疾病的治疗。将讨论针对实体瘤和血液系统恶性肿瘤，狼疮，关节炎，结肠炎，神经系统疾病，疼痛，糖尿病和心血管疾病的JAK实验和临床抑制剂的使用。此外，它将审查该领域和治疗计划中的当前范例，这些范例可以通过Janus激酶的小分子抑制剂加以补充。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号